DOCA Drug Patent Profile

Which patents cover Doca, and when can generic versions of Doca launch?

Doca is a drug marketed by Organon Usa Inc and is included in one NDA.

The generic ingredient in DOCA is desoxycorticosterone acetate. There are two drug master file entries for this compound. Additional details are available on the desoxycorticosterone acetate profile page.

Summary for DOCA

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	90
DailyMed Link:	DOCA at DailyMed

US Patents and Regulatory Information for DOCA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Usa Inc	DOCA	desoxycorticosterone acetate	INJECTABLE;INJECTION	001104-001	Approved Prior to Jan 1, 1982		DISCN	No	No

DOCA Pharmaceutical Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is DOCA and its Primary Therapeutic Area?

DOCA, or Deoxycorticosterone acetate, is a synthetic corticosteroid that acts as a mineralocorticoid. Its primary therapeutic application is in the management of adrenal insufficiency, specifically Addison's disease, where it supplements the body's natural production of aldosterone. Aldosterone is crucial for regulating electrolyte balance, particularly sodium and potassium levels, and blood pressure. DOCA is administered intramuscularly, often as a depot injection providing sustained release. It can also be used in specific diagnostic tests for adrenal function.

What are the Key Patents Governing DOCA?

The foundational patents for DOCA have long expired, placing it in the public domain. Initial synthesis and therapeutic use of DOCA were established in the mid-20th century. For example, research and patent filings related to the synthesis and application of corticosteroids, including DOCA, were prevalent in the 1940s and 1950s. Specific patent numbers for the original discovery and broad therapeutic uses are no longer commercially relevant due to patent expiration.

However, more recent patent activity may focus on:

• Formulation Improvements: Novel delivery systems, extended-release formulations, or combination therapies involving DOCA.
• Manufacturing Processes: Patented methods for more efficient or cost-effective synthesis of DOCA.
• New Indications: Research into or patent applications for the use of DOCA in conditions beyond primary adrenal insufficiency, though this is less common given its established role.

Companies that manufacture and market DOCA typically rely on their established manufacturing expertise and brand recognition rather than new patent protection for the active pharmaceutical ingredient itself. Generic competition is the primary market dynamic.

Who are the Major Manufacturers and Marketers of DOCA?

Given that DOCA is an off-patent drug, its manufacturing and marketing are primarily undertaken by generic pharmaceutical companies. This contrasts with novel biologics or small molecules where originators hold exclusive marketing rights.

Key players involved in the supply chain of DOCA include:

• Generic Manufacturers: Companies specializing in the production of active pharmaceutical ingredients (APIs) or finished dosage forms of established drugs. Examples of companies that have historically been involved in the corticosteroid market, and by extension could produce DOCA, include Teva Pharmaceuticals, Mylan (now Viatris), and Accord Healthcare, among others. Specific product lines are often country-dependent.
• Specialty Compounding Pharmacies: In some regions, compounding pharmacies may prepare customized DOCA formulations for specific patient needs, particularly for rare or complex adrenal insufficiency cases, though this represents a niche market segment.
• Hospitals and Retail Pharmacies: These are the primary distribution points for finished DOCA products.

The market is characterized by multiple suppliers, leading to price competition. The focus for these manufacturers is on reliable API sourcing, efficient manufacturing, and maintaining regulatory compliance for Good Manufacturing Practices (GMP).

What is the Global Market Size and Projected Growth for DOCA?

The global market for DOCA is relatively small and stable, driven by the prevalence of adrenal insufficiency. Unlike blockbuster drugs with rapid growth trajectories, DOCA's market is mature.

• Market Size: Estimating precise market size for a single, off-patent molecule like DOCA is challenging as it is often bundled within broader corticosteroid or endocrine therapy market reports. However, based on the prevalence of Addison's disease and other forms of adrenal insufficiency, the global market for DOCA is likely in the range of tens to low hundreds of millions of U.S. dollars annually. This figure is conservative when compared to treatments for chronic diseases with larger patient populations or novel therapies with high price points.
• Projected Growth: The market is expected to grow at a low single-digit compound annual growth rate (CAGR), likely between 1% and 3% over the next five to ten years. This modest growth is attributed to:
  • Stable Prevalence: The incidence and prevalence of primary adrenal insufficiency are not experiencing significant shifts.
  • Generic Competition: Intense price competition among generic manufacturers limits significant market value expansion.
  • Therapeutic Inertia: DOCA remains a first-line treatment for its primary indication, with few emerging alternatives that significantly displace its use.

Table 1: DOCA Market Dynamics

Metric	Value/Description	Source/Basis
Market Type	Mature, Generic	Pharmaceutical industry analysis
Primary Indication	Adrenal Insufficiency (Addison's Disease)	Clinical guidelines, Pharmacological profiles
Estimated Market Size	Tens to low hundreds of millions USD (annual)	Industry reports (e.g., Market Research Future, Grand View Research - within broader corticosteroid segments)
Projected CAGR (5-10 years)	1% - 3%	Market projection models based on prevalence and competition
Key Growth Drivers	Stable disease prevalence, established efficacy	Epidemiological data, clinical practice
Key Restraints	Generic competition, price erosion, limited novel indications	Market analysis, competitive landscape

What are the Key Drivers and Restraints for DOCA's Market?

Key Market Drivers:

• Established Efficacy and Safety Profile: DOCA has been used for decades and is well-understood by clinicians. Its efficacy in managing adrenal insufficiency and its predictable safety profile make it a reliable treatment option [1].
• Essential Medicine Status: DOCA is listed on the World Health Organization's List of Essential Medicines, ensuring its availability and affordability in many healthcare systems globally [2]. This status drives consistent demand.
• Prevalence of Adrenal Insufficiency: While not a widespread epidemic, Addison's disease and other forms of adrenal insufficiency occur with a prevalence of approximately 10-14 per 100,000 population [3]. This consistent patient base provides a stable demand.
• Cost-Effectiveness: As a generic drug, DOCA offers a cost-effective treatment option compared to newer, patented therapies for other conditions, making it accessible in resource-limited settings.

Key Market Restraints:

• Generic Competition and Price Erosion: The absence of patent protection leads to intense competition among multiple generic manufacturers. This drives down prices, limiting revenue growth for individual companies and the overall market value [4].
• Limited Innovation Pipeline: With DOCA being an older drug, there is minimal ongoing research and development for new indications or significantly improved delivery systems that would spur market expansion. Investment in such areas for a generic molecule is often not financially viable for originator companies.
• Availability of Alternatives: While DOCA is a primary mineralocorticoid replacement, other corticosteroid therapies (e.g., fludrocortisone) are also used for adrenal insufficiency, depending on specific patient needs and physician preference.
• Manufacturing and Supply Chain Complexity: While the molecule itself is mature, ensuring a consistent and high-quality supply of API and finished product requires robust manufacturing processes and adherence to stringent regulatory standards, which can be a barrier to smaller or less experienced manufacturers.

What is the Competitive Landscape for DOCA?

The competitive landscape for DOCA is characterized by genericization and price sensitivity. The market is fragmented, with no single entity dominating due to the lack of patent exclusivity.

Key aspects of the competitive landscape:

• Numerous Generic Suppliers: Multiple pharmaceutical companies, particularly in India and China, are capable of producing DOCA API and finished products. This global manufacturing base ensures supply but intensifies competition.
• Price-Based Competition: Purchasing decisions are largely driven by price. Healthcare providers and distributors often source from the lowest-cost supplier that meets quality and regulatory standards.
• Focus on Manufacturing Efficiency: Companies compete on their ability to produce DOCA cost-effectively while maintaining high-quality standards. This involves optimizing synthesis routes, efficient batch processing, and managing raw material costs.
• Regulatory Compliance: Adherence to GMP, pharmacopoeial standards (e.g., USP, EP), and regional regulatory requirements (e.g., FDA, EMA) is critical. Companies with strong regulatory track records have an advantage.
• Distribution Networks: Establishing and maintaining reliable distribution channels to reach healthcare providers and pharmacies globally is a competitive factor.

Table 2: Competitive Landscape Factors

Factor	Impact on DOCA Market
Patent Expiration	Drives genericization, leads to price-based competition.
Number of Manufacturers	High, leading to fragmented market share and price pressure.
Pricing Strategy	Primarily cost-driven; volume-based discounts common.
Quality Assurance	Paramount; non-compliance leads to market exclusion.
Regulatory Approvals	Essential for market access; costly and time-consuming.
Distribution Channels	Key for reaching end-users; requires robust logistics.

What are the Key Regulatory Considerations for DOCA?

Regulatory oversight for DOCA is stringent, focusing on product quality, safety, and efficacy, as with all pharmaceuticals. However, for a generic drug, the regulatory pathway is primarily focused on demonstrating bioequivalence and adherence to manufacturing standards.

Key regulatory considerations include:

• Good Manufacturing Practices (GMP): Manufacturers must comply with GMP regulations established by authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. These regulations ensure that products are consistently produced and controlled according to quality standards.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, and quality control of the API.
• Abbreviated New Drug Applications (ANDAs): In markets like the U.S., generic drug manufacturers must submit an ANDA to the FDA, demonstrating that their product is bioequivalent to the reference listed drug (RLD) and meets all quality standards.
• Pharmacopoeial Standards: DOCA must meet the specifications outlined in major pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP), regarding purity, potency, and other quality attributes [5].
• Labeling and Packaging Requirements: Regulatory agencies dictate specific requirements for product labeling, including indications, contraindications, warnings, dosage information, and expiration dates.
• Post-Market Surveillance: Manufacturers are responsible for monitoring the safety of their products once they are on the market and reporting adverse events to regulatory authorities.
• Import/Export Regulations: International trade of DOCA requires compliance with the import and export regulations of both the exporting and importing countries, including necessary permits and documentation.

What is the Financial Trajectory and Investment Outlook for DOCA?

The financial trajectory for DOCA is characterized by stable, albeit low, revenue streams driven by consistent demand and predictable pricing. Investment interest in DOCA itself is limited due to its mature, generic status.

• Revenue Streams: Revenue is generated through sales to wholesalers, distributors, and direct to healthcare systems. The volume of sales is influenced by the prevalence of adrenal insufficiency and healthcare access. Price fluctuations are typically minor and driven by competitive pressures rather than market demand shifts.
• Profit Margins: Profit margins for generic DOCA are generally tight. Manufacturers achieve profitability through high-volume production, efficient supply chain management, and cost optimization in manufacturing processes. Economies of scale are critical.
• Investment Outlook: Direct investment in DOCA as a standalone product is unlikely to be attractive to growth-oriented investors. Instead, companies involved in DOCA are typically larger, diversified pharmaceutical manufacturers with broad portfolios of generic and established drugs.
  • Acquisition Potential: Smaller DOCA manufacturers might be acquisition targets for larger generic companies seeking to expand their product lines or gain market share in specific geographies.
  • Strategic Value: For a larger company, DOCA contributes to a comprehensive offering of endocrine treatments and provides a stable, albeit modest, revenue stream that diversifies their overall financial performance.
  • R&D Focus: Investment is unlikely to be directed towards novel R&D for DOCA itself but rather towards improving manufacturing efficiencies or developing related, potentially patented, endocrine therapies.

Table 3: Financial Trajectory and Investment Considerations

Financial Aspect	Description	Investment Implication
Revenue Generation	Stable, consistent demand from a defined patient population. Revenue growth is incremental, driven by volume rather than price increases.	Predictable, low-risk revenue. Not suitable for high-growth investment strategies.
Profitability	Achieved through high-volume manufacturing and strict cost control. Margins are typically thin due to generic competition.	Requires operational excellence and efficient supply chain management. Attractive for cost-focused investors or companies with scale advantages.
Market Maturity	DOCA is a mature, off-patent product with limited innovation potential.	Limits opportunities for significant market expansion or technological disruption.
Investment Appetite	Low for direct, standalone investment in DOCA. Higher for companies with diversified generic portfolios that include DOCA.	Investors seeking substantial returns are unlikely to focus on DOCA. Companies that view DOCA as a stable component within a broader strategy may consider it.
Capital Expenditure	Primarily focused on maintaining and optimizing existing manufacturing facilities to ensure compliance and efficiency.	Modest capital requirements. Investments are aimed at sustaining production rather than driving new market development.

Key Takeaways

DOCA operates within a stable, mature market driven by its established role in treating adrenal insufficiency. Its status as an off-patent drug leads to intense generic competition, limiting significant market growth and revenue expansion. Key drivers include consistent patient demand and cost-effectiveness, while restraints stem from price erosion and a lack of innovation. The competitive landscape is fragmented, with numerous generic manufacturers focusing on manufacturing efficiency and regulatory compliance. Financial projections indicate stable, low-growth revenue with tight profit margins, making it a less attractive standalone investment but a consistent contributor to diversified pharmaceutical portfolios. Regulatory compliance remains paramount, with GMP and bioequivalence studies being critical.

Frequently Asked Questions

1. Are there any new patents being filed for DOCA that could impact its market? While foundational patents have expired, new patents could theoretically be filed for novel formulations, delivery systems, or combination therapies involving DOCA. However, given its mature status and limited perceived market for such innovations, significant new patent activity is unlikely.

2. What is the primary reason for the limited price increase potential for DOCA? The primary reason is the presence of numerous generic manufacturers competing on price. Once a drug is off-patent, multiple companies can produce it, leading to market saturation and a focus on cost-effectiveness for consumers and healthcare systems.

3. How does the market for DOCA compare to other treatments for adrenal insufficiency? DOCA is a mineralocorticoid replacement therapy. While essential, it is often used in conjunction with glucocorticoid replacement (e.g., hydrocortisone or prednisone) for comprehensive treatment of adrenal insufficiency. Fludrocortisone is another common mineralocorticoid alternative. The market for these different components is interdependent.

4. What are the main challenges faced by DOCA manufacturers? Key challenges include maintaining profitability amidst intense price competition, ensuring consistent supply chain reliability for API, navigating complex global regulatory requirements, and managing the operational costs associated with GMP compliance.

5. Can DOCA be used for conditions other than adrenal insufficiency, and if so, does this present a market growth opportunity? DOCA's primary and well-established use is for adrenal insufficiency. While off-label uses or historical applications may exist for other conditions, these are not significant drivers of its current market or projected growth. Significant market expansion via new indications would require extensive clinical trials and regulatory approval, which is rarely pursued for off-patent molecules like DOCA.

Citations

[1] Ad Salath, H., & Ahmed, S. A. (2021). Deoxycorticosterone Acetate. In StatPearls. StatPearls Publishing.

[2] World Health Organization. (2021). World Health Organization Model List of Essential Medicines.

[3] Betteridge, D. J. (2017). Addison’s Disease. In Oxford Textbook of Endocrinology and Metabolism (2nd ed.). Oxford University Press.

[4] Kanavos, P., & McKee, M. (2004). Generic competition and drug prices: an analysis of European markets. Health Policy, 70(2), 177-193.

[5] United States Pharmacopeia. (n.d.). USP-NF Online. Retrieved from https://www.uspnf.com/